A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.
News|Articles|October 10, 2026
Fall Clinical 2026 First Half Recap: Psoriasis, Atopic Dermatitis, and More
Author(s)Tim Smith
Fact checked by: Chelsie Derman
Catch up on HCPLive’s first-half Fall Clinical 2026 coverage, including new psoriasis and atopic dermatitis data and expert insights on HS and vitiligo.
Advertisement
Advertisement
The first half of the
Related to this article
Catch up on HCPLive’s top EADV 2026 psoriasis coverage, from head-to-head TYK2 inhibitor data to 2-year oral IL-23 results in high-impact disease sites.
Raj Chovatiya, MD, PhD, discusses biologic choice in atopic dermatitis, pipeline strategies, and remibrutinib’s approval for symptomatic dermographism.
New ARCADIA and OLYMPIA LTE data show nemolizumab sustained skin clearance and itch relief for up to 3 years in atopic dermatitis and prurigo nodularis.
Two-year ICONIC-LEAD data show oral icotrokinra sustained PASI 90 and IGA 0/1 responses in more than 70% of adults and adolescents with plaque psoriasis.
New TOGETHER-PsO data show ixekizumab plus tirzepatide drove broader immune and metabolic biomarker changes than ixekizumab alone in psoriasis and obesity.
Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.
In pooled, propensity-matched data, SC infliximab achieved week 54 endoscopic response in 65.7% of patients with ileal Crohn’s disease vs 27.1% with IV.
Advertisement
Advertisement